News
Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
4h
Philstar Life on MSNObesity therapies you should knowI understand how it feels to be bullied because of one’s weight. I have been there. However, at that time, I was also ...
Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...
The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...
The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.
All these drugs are very effective and they’ve become a game changer for people who need to lose weight. Get on the drug, eat ...
Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...
With age comes wisdom. But you know what else can come with age? Weight gain. Losing weight can also be harder as you grow ...
Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.
The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results